Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.

MLA

Shin, Seunghwan, et al. “Exploring Expression Levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 Cancer Types Using an Artificial Intelligence-Powered Immunohistochemistry Analyzer.” Journal of Clinical Oncology, vol. 41, June 2023, p. 3135. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.3135.

APA

Shin, S., Cho, S. I., Choi, S., Lee, T., Kim, S., Jung, W., Mostafavi, M., Brattoli, B., Ryu, J., Park, S., Pereira, S., Nesmith, K., Park, J., Seo, M. S., Kim, H., Kim, S., & Ock, C.-Y. (2023). Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer. Journal of Clinical Oncology, 41, 3135. https://doi.org/10.1200/JCO.2023.41.16_suppl.3135

Chicago

Shin, Seunghwan, Soo Ick Cho, Sangjoon Choi, Taebum Lee, Seulki Kim, Wonkyung Jung, Mohammad Mostafavi, et al. 2023. “Exploring Expression Levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 Cancer Types Using an Artificial Intelligence-Powered Immunohistochemistry Analyzer.” Journal of Clinical Oncology 41 (June): 3135. doi:10.1200/JCO.2023.41.16_suppl.3135.